期刊簡介 | |||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | MOLECULAR HUMAN REPRODUCTION LetPub Score 6.4
50 ratings
Rate
Reputation 7.6 Influence 5.2 Speed 7.0 | ||||||||||||||||||||||||||||||||||||||||
期刊簡稱 | MOL HUM REPROD | ||||||||||||||||||||||||||||||||||||||||
ISSN | 1360-9947 | ||||||||||||||||||||||||||||||||||||||||
E-ISSN | 1460-2407 | ||||||||||||||||||||||||||||||||||||||||
h-index | 113 | ||||||||||||||||||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||||||||||||||||||
自引率 (2023-2024) | 2.80%自引率趨勢 | ||||||||||||||||||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||||||||||||||||||
官方網站 | http://molehr.oxfordjournals.org/ | ||||||||||||||||||||||||||||||||||||||||
在線稿件提交 | http://mc.manuscriptcentral.com/molehr | ||||||||||||||||||||||||||||||||||||||||
開放訪問 | No | ||||||||||||||||||||||||||||||||||||||||
出版商 | Oxford University Press | ||||||||||||||||||||||||||||||||||||||||
主題領域 | 生物 | ||||||||||||||||||||||||||||||||||||||||
出版國/地區 | UNITED STATES | ||||||||||||||||||||||||||||||||||||||||
發行頻率 | 月刊 | ||||||||||||||||||||||||||||||||||||||||
創刊年 | 1995 | ||||||||||||||||||||||||||||||||||||||||
每年文章數 | 43每年文章數趨勢 | ||||||||||||||||||||||||||||||||||||||||
黃金OA百分比 | 18.45% | ||||||||||||||||||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1360-9947%5BISSN%5D | ||||||||||||||||||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||||||||||||||||||||||||||
競爭力 * | 來自作者的數據: Ordinary | ||||||||||||||||||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[MOLECULAR HUMAN REPRODUCTION] 的評論 | 撰寫評論 |
作者: 神照天真 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-03-24 19:08:41 評論於 Review speed: 2.0 | Submission hit rate: 75.0 Emphasized research direction: sperm function Experience sharing: In the mid-2022, I submitted an uninvited review. Both the first and second reviews took two weeks each, and it only took two months from submission to acceptance. I chose non-OA, did not polish, did not check for plagiarism (in fact, during the proofreading stage, the editor helped correct many language and grammar errors, essentially providing free polishing), and did not spend a penny. Reviewer 1 in the first review: The article is concise, and I recommend publication. The review was very detailed, pointing out each reference citation and providing suggestions on which references to use, as well as teaching me how to rewrite some sentences. Clearly a very familiar figure in this field, as most of the article discusses the work of his research group. Reviewer 2: The article is simplistic, and I do not recommend publication. In fact, this reviewer directly pointed out the biggest flaw in this article, the lack of depth. He raised several major issues, but following his suggestions would essentially require a rewrite. Therefore, I provided some reasons to refute his points and chose not to make changes. I thought pleasing reviewer 1 would satisfy the editor. Second review in two weeks: Once again, the article was sent back to reviewer 1, who helped correct many grammar errors and the editor promptly gave an "accepted with minor revision" verdict. Summary: This journal not only has high quality but also operates efficiently. It is possible to choose non-OA, and it was in category 3 when submitted, but moved up to category 2 a few months later. The impact factor has been steadily increasing, and there is hope of it breaking the 5 mark next year(0) 讚! | 神照天真 |
作者: 水月潇郡 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-07-12 12:07:52 評論於 The choice between open access (OA) and non-OA for this journal is up to the authors. If you choose non-OA in the system, you do not need to pay any publication fees(0) 讚! | 水月潇郡 |
作者: 形意士鹏 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-03-30 16:45:02 評論於 Not choosing OA, it's free(0) 讚! | 形意士鹏 |
作者: 水月潇郡 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-01-21 23:53:19 評論於 Nonsense(0) 讚! | 水月潇郡 |
作者: 控鹤冬山 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-01-21 22:41:47 評論於 Am I talking nonsense and can get money???(0) 讚! | 控鹤冬山 |
作者: 控鹤冬山 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-01-21 21:21:24 評論於 I'm not sure(0) 讚! | 控鹤冬山 |
作者: 控鹤冬山 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-01-21 14:04:10 評論於 Yes(0) 讚! | 控鹤冬山 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 18:18:16 評論於 All questions must be answered one by one without omission; strive to meet the additional experiments suggested in the comments, and provide reasonable reasons if they cannot be met; the literature recommended by the reviewers must be cited and thoroughly discussed; after revising, make sure to check the corrections made in the initial draft before submitting(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 16:50:12 評論於 After the reviewers have completed scoring the chapter, they need to write a comprehensive review opinion. This opinion usually includes a brief summary of the article, an evaluation of the innovative points of the article, corrections to the shortcomings of the article, and suggestions for the editorial team on how to handle this article(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 魂魄彦露 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 16:28:59 評論於 What are the opinions and suggestions of journal editors? What are the opinions and suggestions of reviewers? What are the differences between the two?(0) 讚! | 魂魄彦露 |
作者: 北国博达 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 21:39:04 評論於 How to respond to reviewers' comments?(0) 讚! | 北国博达 |
作者: 艳芳三岁啦 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-21 15:06:31 評論於 What is the length of your submission cycle?(0) 讚! | 艳芳三岁啦 |
作者: 龙鳞滢渟 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-11-03 09:34:15 評論於 Are there more color images?(0) 讚! | 龙鳞滢渟 |
作者: 之卉Sama 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-08-05 14:01:32 評論於 What is the requirement for plagiarism check for this magazine?(0) 讚! | 之卉Sama |
作者: 奥蒂莉亚麦当劳 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-07-24 23:14:23 評論於 Review speed: 1.0 | Submission acceptance rate: 50.0 Weighted research direction: Reproductive experience sharing: None(0) 讚! | 奥蒂莉亚麦当劳 |
作者: 控鹤冬山 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-05-23 11:00:01 評論於 The layout fee is almost 20,000 yuan, it's so expensive(0) 讚! | 控鹤冬山 |
作者: 北风树遥 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2020-11-18 18:58:50 評論於 How long does it take for the final decision to come? It has been under review for a month, hoping for good news(0) 讚! | 北风树遥 |
作者: 瑞珺来了 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2020-01-21 15:57:11 評論於 Hurry up, the first trial is in January, but there are many questions raised, and it is even inconvenient to answer(0) 讚! | 瑞珺来了 |
作者: 子睿mio 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-08-15 18:42:16 評論於 Is this magazine fast?(0) 讚! | 子睿mio |
作者: 书生飞双 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-07-06 08:03:03 評論於 I need someone experienced to share their advice. My submission has been in super slow mode for a month now and has reverted back to "Awaiting Reviewer Selection"; I have no idea what's going on. Sigh, my heart is broken(0) 讚! | 书生飞双 |
作者: 是你的建弼呀 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-10-30 23:46:34 評論於 Review Speed: 2.0 | Acceptance Rate: 50.0 Sharing Experience: 5 year Impact Factor 3.517(0) 讚! | 是你的建弼呀 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2011-06-29 11:25:03 評論於 Bullish, if it rises again tomorrow, it may break through 3 points(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2010-02-26 16:20:04 評論於 A few years ago I published it, not in a peer review journal. If you want to take the paper abroad, then I suggest changing it. If you just want to publish, then it's still okay(0) 讚! | 凌霄高洁 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us